Compare BTOC & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTOC | APRE |
|---|---|---|
| Founded | 2020 | 2006 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 11.5M |
| IPO Year | 2023 | 2019 |
| Metric | BTOC | APRE |
|---|---|---|
| Price | $0.28 | $0.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.00 | ★ $4.10 |
| AVG Volume (30 Days) | ★ 196.1K | 191.7K |
| Earning Date | 05-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $190,408,258.00 | N/A |
| Revenue This Year | $34.89 | N/A |
| Revenue Next Year | $14.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 14.03 | N/A |
| 52 Week Low | $0.23 | $0.55 |
| 52 Week High | $1.78 | $2.22 |
| Indicator | BTOC | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 43.25 |
| Support Level | $0.27 | $0.75 |
| Resistance Level | $0.34 | $0.81 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 21.44 | 6.77 |
Armlogi Holding Corp is a fast-growing U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions relating to warehouse management and order fulfillment. The company provides one-stop warehousing and logistics services to cross-border e-commerce merchants outside the U.S. who seek to sell in the U.S. market. The warehouses are equipped with automated sorting systems, heavy-duty forklifts, and pallets and trays that are suitable for processing bulky items. The services of the company include customs brokerage services, transportation of merchandise to U.S. warehouses, and warehouse management and order fulfillment services.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.